Status:
UNKNOWN
Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University
Conditions:
CD19-chimeric Antigen Receptor T Cells
Relapsed and/or Refractory Acute Lymphoblastic Leukemia
Eligibility:
All Genders
Phase:
NA
Brief Summary
Building a new haploid transplanted model with high-dose CTX、CD19-CART,donor CD34+ hematopoietic stem cell and Tregs,to prevent graft-versus-host disease(GVHD),reduce the infection,promote the rate of...
Detailed Description
compare the new haplo-HSCT model with the traditional haplo-HSCT in DFS、OS、RFS、CR and the degree of GVHD.etc.for the r/r B-ALL patients.
Eligibility Criteria
Inclusion
- the r/r B-ALL patients
- have the healthy allo-HSCT donor
- voluntary and signed the treatment protocol
Exclusion
- not match the inclusion criteria
- important organ is dysfunction, such as heart and/or renal dysfunction,liver failure
- Pregnancy or breast-feeding women
- has virus infection,such as HIV,hepatitis virus,and can not be cleared with anti-virus treatment
Key Trial Info
Start Date :
May 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03423706
Start Date
May 7 2018
End Date
December 1 2021
Last Update
December 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First affiliated hospital of Harbin medical university
Harbin, Heilongjiang, China, 150001